These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 12421815)

  • 1. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis.
    Lambert G; Amar MJ; Guo G; Brewer HB; Gonzalez FJ; Sinal CJ
    J Biol Chem; 2003 Jan; 278(4):2563-70. PubMed ID: 12421815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding.
    Li G; Thomas AM; Williams JA; Kong B; Liu J; Inaba Y; Xie W; Guo GL
    PLoS One; 2012; 7(4):e35895. PubMed ID: 22540009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
    Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
    J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
    Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
    J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors.
    Ricketts ML; Boekschoten MV; Kreeft AJ; Hooiveld GJ; Moen CJ; Müller M; Frants RR; Kasanmoentalib S; Post SM; Princen HM; Porter JG; Katan MB; Hofker MH; Moore DD
    Mol Endocrinol; 2007 Jul; 21(7):1603-16. PubMed ID: 17456796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
    Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
    Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity.
    Guo GL; Lambert G; Negishi M; Ward JM; Brewer HB; Kliewer SA; Gonzalez FJ; Sinal CJ
    J Biol Chem; 2003 Nov; 278(46):45062-71. PubMed ID: 12923173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor is essential for normal glucose homeostasis.
    Ma K; Saha PK; Chan L; Moore DD
    J Clin Invest; 2006 Apr; 116(4):1102-9. PubMed ID: 16557297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of farnesoid X receptor during the acute phase response.
    Kim MS; Shigenaga J; Moser A; Feingold K; Grunfeld C
    J Biol Chem; 2003 Mar; 278(11):8988-95. PubMed ID: 12519762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia.
    Zhang Y; Yin L; Anderson J; Ma H; Gonzalez FJ; Willson TM; Edwards PA
    J Biol Chem; 2010 Jan; 285(5):3035-43. PubMed ID: 19996107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.
    Bilz S; Samuel V; Morino K; Savage D; Choi CS; Shulman GI
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E716-22. PubMed ID: 16291572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase.
    Li H; Xu G; Shang Q; Pan L; Shefer S; Batta AK; Bollineni J; Tint GS; Keller BT; Salen G
    Metabolism; 2004 Jul; 53(7):927-32. PubMed ID: 15254889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice.
    Hanniman EA; Lambert G; McCarthy TC; Sinal CJ
    J Lipid Res; 2005 Dec; 46(12):2595-604. PubMed ID: 16186601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis.
    Ling CJ; Xu JY; Li YH; Tong X; Yang HH; Yang J; Yuan LX; Qin LQ
    Food Funct; 2019 Nov; 10(11):7299-7307. PubMed ID: 31626262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
    Kast HR; Nguyen CM; Sinal CJ; Jones SA; Laffitte BA; Reue K; Gonzalez FJ; Willson TM; Edwards PA
    Mol Endocrinol; 2001 Oct; 15(10):1720-8. PubMed ID: 11579204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.
    Sinal CJ; Tohkin M; Miyata M; Ward JM; Lambert G; Gonzalez FJ
    Cell; 2000 Sep; 102(6):731-44. PubMed ID: 11030617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis.
    Xu J; Li Y; Chen WD; Xu Y; Yin L; Ge X; Jadhav K; Adorini L; Zhang Y
    Hepatology; 2014 May; 59(5):1761-1771. PubMed ID: 24038130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesoid X receptor antagonist exacerbates dyslipidemia in mice.
    Amano Y; Yamakawa H; Yonemori K; Shimada M; Tozawa R
    Pharmacol Rep; 2018 Feb; 70(1):172-177. PubMed ID: 29367104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.